<DOC>
	<DOCNO>NCT00002460</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block uptake estrogen . PURPOSE : Phase III trial compare effectiveness adjuvant therapy use tamoxifen ovarian ablation goserelin treat woman stage I stage II breast cancer .</brief_summary>
	<brief_title>Adjuvant Hormone Therapy Treating Women With Operable Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine , prospective , randomize , control trial whether administration course adjuvant tamoxifen ablation ovarian function result prolongation time recurrence death patient 50 year age operable carcinoma breast . II . Determine hormone manipulation affect mood sexual functioning patient . OUTLINE : This randomize study . Patients stratify clinician . All patient randomize follow primary therapy , , addition surgery , may include local irradiation , perioperative cyclophosphamide , 6 cycle cyclophosphamide , methotrexate , fluorouracil ( CMF ) high-risk patient . Clinicians may elect randomize patient group group include tamoxifen . The first group receive therapy . Then second group receive tamoxifen daily least 2 year . The third group receive ovarian ablation goserelin via monthly injection least 2 year . The final group receive ovarian ablation goserelin plus daily tamoxifen least 2 year . All patient follow every 3 month 2 year , every 6 month 3 year , annually . PROJECTED ACCRUAL : 800 1,000 patient enter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Operable , clinical Stage I/II breast cancer ( T13 , N01 , M0 ) No evidence distant metastasis xray chest , spine , pelvis Bone scan evidence alone secondary mass allow unless consider unequivocal evidence metastasis No primary carcinoma fix underlying muscle chest wall No deeply fix axillary node No ulceration , skin infiltration , peau d'orange involve 1/3 breast No bilateral tumor Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Under 50 Sex : Women Menopausal status : Any status Performance status : Not specify Life expectancy : No limit life expectancy due intercurrent illness Hematopoietic : WBC least 3,000 Platelets least 90,000 Hemoglobin least 10 g/dL Hepatic : Normal liver function require Renal : Normal kidney function require Other : Fit surgery No prior treatment malignancy except : Nonmelanomatous skin cancer Conebiopsied situ carcinoma cervix Englishspeaking patient eligible qualityoflife assessment PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Chemotherapy highrisk patient allow discretion clinician Endocrine therapy : At least 6 week since prior hormonal therapy No concomitant hormonal therapy include oral contraceptive ( patient must discontinue pill 2 year ) Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>